Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
64.70
+0.85 (+1.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
46
47
Next >
5 Safe Stocks Under $40 to Buy Immediately
August 21, 2023
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now.
Via
InvestorPlace
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
August 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
August 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
August 11, 2023
Via
Benzinga
How Is The Market Feeling About Gilead Sciences?
August 10, 2023
Via
Benzinga
2 High-Yield Dividend Stocks to Buy on the Dip
August 08, 2023
The market may have been a bit too harsh on these stocks.
Via
The Motley Fool
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
August 04, 2023
GILD earnings call for the period ending June 30, 2023.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
August 17, 2023
Via
Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
August 17, 2023
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Via
Benzinga
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
August 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
The 3 Best Biotech Stocks to Buy in August
August 09, 2023
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news.
Via
InvestorPlace
Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?
August 03, 2023
Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs.
Via
Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
July 31, 2023
Via
Benzinga
Expert Ratings for Gilead Sciences
July 24, 2023
Via
Benzinga
Hypertrophic Cardiomyopathy Therapeutics Market Projected to Show Strong Growth : Novartis, Gilead Sciences, ADVANZ PHARMA
August 08, 2023
Stay up-to-date with Hypertrophic Cardiomyopathy Therapeutics Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation
August 04, 2023
Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by...
Via
Benzinga
Gilead Sciences Announces Second Quarter 2023 Financial Results
August 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
August 03, 2023
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost.
Via
Benzinga
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
August 04, 2023
Amazon, ELF and CAT were earnings winners, but there were big losers too.
Via
Investor's Business Daily
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
August 01, 2023
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.
Via
InvestorPlace
3 Stocks Retirees Should Absolutely Love
July 29, 2023
These stocks offer solid income plus more.
Via
The Motley Fool
7 Best Cancer Stocks to Invest in Now
July 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Via
MarketBeat
Topics
Death
Exposures
Death
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
July 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
July 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer
July 24, 2023
Gilead Sciences Inc (NASDAQ: GILD) decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility
Via
Benzinga
Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling
July 24, 2023
The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives
July 23, 2023
DeSantis made it clear that he thinks companies should only maximize profit and be subject to shareholder lawsuits if they do anything other than maximizing profits. So how does this get us to suing...
Via
Talk Markets
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
July 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.